

Statement of Use

Statement of Use
Document 14-21 REF V-01

bit.bio
The Dorothy Hodgkin Building
Babraham Research Campus
Cambridge CB22 3FH
United Kingdom
www.bit.bio

Customer support:
technical@bit.bio
orders@bit.bio

Statement of Use

Bit Bio Limited ("bit.bio") supplies high-quality mature human cells differentiated from a human induced pluripotent stem cell (hiPSC) line for research use. The parental hiPSC line was derived from dermal fibroblasts obtained from a white male donor and transduced with replication-deficient retroviral vectors expressing the four Yamanaka factors (OCT4, SOX2, KLF4, MYC). bit.bio has obtained the relevant commercial license covering use of this parental hiPSC line and cells derived from it.

Ethical considerations and donor protection

The specimen used to generate the parental hiPSC cell line used by bit.bio to generate mature human cells of various types was collected with the informed consent of both the collection site and the individual donor(s), under good clinical practice, and in accord with all applicable law. Any personally identifiable health information collected from the donor(s) during specimen collection was anonymized consistent with the provisions of the Health Insurance Portability and Accessibility Act (HIPAA) and/or the General Data Protection Regulation, as applicable, and in any case, has not been shared with bit.bio.

bit.bio opti-ox™ cellular reprogramming

bit.bio's precise method of cellular reprogramming of the parental hiPSC line towards mature cell types is via a dual safe harbor engineering approach termed "opti-ox™". The opti-ox™ system uses CRISPR/Cas9 to insert two separate recombinant gene expression cassettes into two different genomic safe harbor sites. bit.bio has obtained commercial licenses for the opti-ox™ platform technology and various related components from, among others, Cambridge Enterprise, Limited; ERS Genomics, Limited; iPS Academia Japan, Inc.; and TET Systems GmbH & Co.

All mature human cells manufactured by bit.bio are produced according to strict aseptic bio-banking procedures. Each manufactured cell lot is tested for sterility and absence of mycoplasma infection, both at the cryopreservation and post-thawing stages, as well as for the presence of certain common pathogens (i.e., hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus-1 (HIV-1), human immunodeficiency virus-2 (HIV-2)). As a precaution, all bit.bio cell products should be handled under biosafety level 1 (BSL1) containment at a minimum, as with all cells derived from human or other primate material.

By taking delivery of the cells provided, the recipient agrees:

1. The cells will not be used in human subjects, administered to human subjects in clinical trials, or administered for diagnostic purposes involving human subjects;
2. The cells will be used only in compliance with applicable laws and regulations, and in compliance with recipients' applicable policies on research involving human subjects;
3. In the case of entities receiving funding from the United States federal government to conduct human stem cell research, be used in compliance with all federal, state, and local laws and regulations and

the NIH Guidelines on Human Stem Cell Research (available at <http://stemcells.nih.gov/policy>), each as applicable;

4. The cells will not be used in research in which they are introduced into blastocysts from non-human primates; and
5. The cells will not be used in research involving the breeding of animals where the introduction of the material may contribute to the germ line.

If you require more information, please contact bit.bio at info@bit.bio

Statement of Use
Document 14-21 REF V-01

bit.bio
The Dorothy Hodgkin Building
Babraham Research Campus
Cambridge CB22 3FH
United Kingdom
www.bit.bio

Customer support:
technical@bit.bio
orders@bit.bio